Completed PHASE1 NCT00058526

A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

A Multicenter Phase I Open-label Dose-escalation Vaccine Trial of dHER2 Protein With AS15 Adjuvant in HER2-overexpressing Patients With High-risk Breast Cancer

Sponsor: GlaxoSmithKline

Conditions Neoplasms, Breast

Interventions Immunotherapeutic SB719125 (Primary)

Updated 8 times since 2017 Last updated: May 12, 2017 Started: Mar 20, 2003 Primary completion: Sep 6, 2006 Completion: Sep 6, 2006

Listed as NCT00058526, this PHASE1 trial focuses on Neoplasms, Breast and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Jul 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boca Raton, United States , Brussels, Belgium , Buffalo, United States , Charleroi, Belgium , Charlotte, United States , East Melbourne, Australia , Footscray, Australia , Heidelberg, Australia , Leuven, Belgium , Lyon, France and 6 more locations